keyword
https://read.qxmd.com/read/38308625/a-systematic-review-of-the-real-world-effectiveness-and-economic-and-humanistic-outcomes-of-selected-oral-antipsychotics-among-patients-with-schizophrenia-in-the-united-states-updating-the-evidence-and-gaps
#1
REVIEW
Ki Jin Jeun, Khalid M Kamal, Keyuri Adhikari, David A Nolfi, Md Najeeb Ashraf, Christopher Zacker
BACKGROUND: Schizophrenia is a chronic, relapsing, and burdensome psychiatric disorder affecting approximately 0.25%-0.6% of the US population. Oral antipsychotic treatment (OAT) remains the cornerstone for managing schizophrenia. However, nonadherence and high treatment failure lead to increased disease burden and medical spending. Cost-effective management of schizophrenia requires understanding the value of current therapies to facilitate better planning of management policies while addressing unmet needs...
February 3, 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38291403/effect-of-single-administration-of-d-sorbitol-pretreatment-on-the-bitterness-and-continued-willingness-to-take-asenapine-a-randomized-single-blind-placebo-controlled-crossover-trial
#2
JOURNAL ARTICLE
Shuhei Wada, Kunihiro Iwamoto, Hiroki Okumura, Hirotake Hida, Shuichi Hiraoka, Aya Kamei, Daisuke Mori, Kiyofumi Yamada, Masahiko Ando, Norio Ozaki, Masashi Ikeda
BACKGROUND: Asenapine has unique orally-related side effects, such as a bitter taste induced by sublingual administration, which often results in discontinuation of the medication. While the FDA has approved black-cherry-flavored asenapine, several countries have prescribed only unflavored versions. Specifically, Asians commonly report experiencing the bitterness of asenapine because they are more sensitive to bitter tastes than other ethnic groups. In this study, with the aim of improving adherence by reducing the bitterness of asenapine, we investigated the effects of D-sorbitol, which reduced the bitterness parameters of taste sensors in our previous basic study on the bitterness and continuity of asenapine among patients with schizophrenia...
January 30, 2024: BMC Psychiatry
https://read.qxmd.com/read/38239112/asenapine-versus-olanzapine-for-the-treatment-of-nausea-and-vomiting-in-patients-with-cancer-a-retrospective-study
#3
JOURNAL ARTICLE
Tomohiko Kimura, Akifumi Kanai, Hiroyuki Muraoka, Yuichiro Takahashi, Masatomo Ara, Ken Inada
AIM: Patients with cancer often experience nausea and vomiting (N/V), but may have difficulty using olanzapine (OLZ), a common antiemetic. Asenapine (ASE) is a multi-acting receptor-targeted antipsychotic like OLZ, although there is little evidence that ASE serves as an antiemetic. The aim of this study was to evaluate the efficacy and tolerability of ASE compared to those of OLZ for the treatment of N/V in patients with cancer. METHODS: This retrospective study involved patients who received 5 mg ASE, 5 mg OLZ, or 2...
January 19, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38238829/structure-based-virtual-screening-study-for-identification-of-potent-insecticides-against-the-anopheles-gambiae-to-combat-the-malaria
#4
JOURNAL ARTICLE
Nawal Helmi
BACKGROUND OBJECTIVES: Vector-borne infectious diseases contribute significantly to global mortality, with over 700,000 annual deaths, and malaria alone accounts for more than 400,000 of these fatalities. Anopheles gambiae, a prominent mosquito species, serves as a primary vector for transmitting malaria to humans. To address this issue, researchers have identified the D1-like dopamine receptor (DAR), specifically DOP2, as a promising target for developing new insecticides. METHODS: The three-dimensional structure of DOP2 from A...
January 16, 2024: Journal of Vector Borne Diseases
https://read.qxmd.com/read/38211745/a-systematic-review-and-network-meta-analysis-on-comparative-efficacy-acceptability-and-safety-of-treatments-in-acute-bipolar-mania-in-youths
#5
REVIEW
Selma Tural Hesapcioglu, Meryem Kasak, Helin Abursu, Seda Kafali, Mehmet Fatih Ceylan, Mesut Akyol
BACKGROUND: The evidence of treatment options' efficacy on acute bipolar manic episodes is relatively less in youths than adults. We aimed to compare and rank the drug's efficacy, acceptability, tolerability, and safety for acute mania in children and adolescents. METHOD: We systematically reviewed the double-blinded, randomized controlled trials (RCTs) comparing drugs or placebo for acute manic episodes of bipolar disorder in children and adolescents using PRISMA guidelines...
January 10, 2024: Journal of Affective Disorders
https://read.qxmd.com/read/38168118/molecular-basis-of-human-trace-amine-associated-receptor-1-activation
#6
JOURNAL ARTICLE
Gregory Zilberg, Alexandra K Parpounas, Audrey L Warren, Shifan Yang, Daniel Wacker
The human trace amine-associated receptor 1 (hTAAR1, hTA1) is a key regulator of monoaminergic neurotransmission and the actions of psychostimulants. Despite preclinical research demonstrating its tractability as a drug target, its molecular mechanisms of activation remain unclear. Moreover, poorly understood pharmacological differences between rodent and human TA1 complicate the translation of findings from preclinical disease models into novel pharmacotherapies. To elucidate hTA1's mechanisms on the molecular scale and investigate the underpinnings of its divergent pharmacology from rodent orthologs, we herein report the structure of the human TA1 receptor in complex with a Gαs heterotrimer...
January 2, 2024: Nature Communications
https://read.qxmd.com/read/37986760/molecular-basis-of-human-trace-amine-associated-receptor-1-activation
#7
Gregory Zilberg, Alexandra K Parpounas, Audrey L Warren, Shifan Yang, Daniel Wacker
The human trace amine-associated receptor 1 (hTAAR1, hTA1) is a key regulator of monoaminergic neurotransmission and the actions of psychostimulants. Despite preclinical research demonstrating its tractability as a drug target, its molecular mechanisms of activation remain unclear. Moreover, poorly understood pharmacological differences between rodent and human TA1 complicate the translation of findings from preclinical disease models into novel pharmacotherapies. To elucidate hTA1's mechanisms on the molecular scale and investigate the underpinnings of its divergent pharmacology from rodent orthologs, we herein report the structure of the human TA1 receptor in complex with a Gαs heterotrimer...
September 7, 2023: bioRxiv
https://read.qxmd.com/read/37926930/optimal-dose-for-the-efficacy-of-asenapine-in-patients-with-schizophrenia-real-world-data
#8
JOURNAL ARTICLE
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa, Masaki Kato, Toshihiko Kinoshita
AIMS: A meta-analysis of short-term studies revealed no significant differences between the doses of asenapine, 10 and 20 mg/day, in the acute treatment of schizophrenia. However, it should be noted that many patients from clinical practice were excluded, and the dose-response to asenapine in a real-world setting is still unclear. Additionally, the dose-response in the maintenance phase is not clear. This study aimed to evaluate the differences in the efficacy of different asenapine doses in patients with maintenance phase of schizophrenia in a real-world setting...
November 5, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37815563/diagnosis-and-treatment-of-bipolar-disorder-a-review
#9
REVIEW
Andrew A Nierenberg, Bruno Agustini, Ole Köhler-Forsberg, Cristina Cusin, Douglas Katz, Louisa G Sylvia, Amy Peters, Michael Berk
IMPORTANCE: Bipolar disorder affects approximately 8 million adults in the US and approximately 40 million individuals worldwide. OBSERVATIONS: Bipolar disorder is characterized by recurrent episodes of depression and mania or hypomania. Bipolar depressive episodes are similar to major depressive episodes. Manic and hypomanic episodes are characterized by a distinct change in mood and behavior during discrete time periods. The age of onset is usually between 15 and 25 years, and depression is the most frequent initial presentation...
October 10, 2023: JAMA
https://read.qxmd.com/read/37391174/umbrella-review-association-between-antipsychotic-drugs-and-metabolic-syndrome-hallmarks-in-children-and-adolescents
#10
JOURNAL ARTICLE
Carla Carnovale, Vera Battini, Claudia Santoro, Maria Pia Riccio, Sara Carucci, Maria Nobile, Pietro Formisano, Carmela Bravaccio, Alessandro Zuddas, Emilio Clementi, Marco Pozzi, Simone Pisano
OBJECTIVE: To summarize the available evidence on metabolic parameters indicating metabolic adverse effects and risk of metabolic syndrome in children and adolescents treated with antipsychotics, following a pre-specified protocol (PROSPERO ID 252336). METHOD: We searched PubMed, Embase and PsycINFO until May 14, 2021, to identify systematic reviews (SR), meta-analyses (MA) and network meta-analyses (NMA) examining symptoms associated to metabolic syndrome in patients <18 years of age who required treatment with oral antipsychotic drugs...
June 23, 2023: Journal of the American Academy of Child and Adolescent Psychiatry
https://read.qxmd.com/read/37232002/long-term-safety-and-efficacy-of-sublingual-asenapine-for-the-treatment-of-schizophrenia-a-phase-iii-extension-study-with-follow-up-for-52-weeks-p06125-secondary-publication
#11
JOURNAL ARTICLE
Toshihiko Kinoshita, Yoshiteru Takekita, Shuichi Hiraoka, Fumihiro Tamura, Yasuhiro Iwama
After completion of a 6-week double-blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open-label study evaluated the safety and efficacy of a 52-week treatment with asenapine at flexible doses. In 201 subjects, including 44 who had received placebo (P/A group) and 157 who had received asenapine (A/A group) in the feeder trial, adverse events occurred at rates of 90.9% and 85.4% and serious adverse events at rates of 11...
May 25, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37159349/long-term-efficacy-of-antipsychotic-drugs-in-initially-acutely-ill-adults-with-schizophrenia-systematic-review-and-network-meta-analysis
#12
JOURNAL ARTICLE
Stefan Leucht, Johannes Schneider-Thoma, Angelika Burschinski, Natalie Peter, Dongfang Wang, Shimeng Dong, Maximilian Huhn, Adriani Nikolakopoulou, Georgia Salanti, John M Davis
Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation...
June 2023: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
https://read.qxmd.com/read/37102321/narrative-review-of-the-advances-in-the-pharmacotherapeutic-management-of-juvenile-onset-schizophrenia
#13
JOURNAL ARTICLE
Chesika J Crump, Megan E Good, Hagar Abuelazm, Rif S El-Mallakh
INTRODUCTION: Schizophrenia usually begins with prodromal symptoms in adolescence. In 39% of patients, onset of psychotic symptoms occurs prior to age 19. Advances in the treatment of psychosis with medications over the last decade are reviewed in this paper. AREAS COVERED: Understanding how to prescribe antipsychotics early in schizophrenia requires an understanding of the pathophysiology of the disease. The current structure of the dopamine hypothesis is reviewed...
May 1, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946229/an-update-on-potential-pharmacotherapies-for-cognitive-impairment-in-bipolar-disorder
#14
REVIEW
Danica E Johnson, Roger S McIntyre, Rodrigo B Mansur, Joshua D Rosenblat
INTRODUCTION: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optimal socio-occupational functioning and reducing quality of life. Presently, there are no efficacious treatments for cognitive impairment in BD, but many pharmacological interventions are being considered as they have the potential to target the underlying pathophysiology of the disorder. AREAS COVERED: This review summarizes the available evidence for pharmacological interventions for cognitive impairment in bipolar disorder...
April 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36918838/sensory-evaluation-of-the-bitterness-of-asenapine-using-d-sorbitol-pretreatment-single-blind-placebo-controlled-crossover-trial
#15
JOURNAL ARTICLE
Shuhei Wada, Kunihiro Iwamoto, Hiroki Okumura, Hirotake Hida, Shuichi Hiraoka, Aya Kamei, Daisuke Mori, Kiyofumi Yamada, Norio Ozaki
BACKGROUND: Antipsychotics are essential in the acute treatment of and maintenance therapy for schizophrenia, but medication adherence and long-term treatment continuity are needed to maximize their effectiveness. Each antipsychotic has various side effects, which may affect adherence. Some patients with schizophrenia are reluctant to take asenapine because of its unique oral-related side effects, such as the bitter taste caused by sublingual administration. Our previous basic research found that D-sorbitol lowered the bitterness parameters of the taste sensors...
March 14, 2023: BMC Psychiatry
https://read.qxmd.com/read/36901803/a-postsynaptic-density-immediate-early-gene-based-connectome-analysis-of-acute-nmdar-blockade-and-reversal-effect-of-antipsychotic-administration
#16
JOURNAL ARTICLE
Annarita Barone, Giuseppe De Simone, Mariateresa Ciccarelli, Elisabetta Filomena Buonaguro, Carmine Tomasetti, Anna Eramo, Licia Vellucci, Andrea de Bartolomeis
Although antipsychotics' mechanisms of action have been thoroughly investigated, they have not been fully elucidated at the network level. We tested the hypothesis that acute pre-treatment with ketamine (KET) and administration of asenapine (ASE) would modulate the functional connectivity of brain areas relevant to the pathophysiology of schizophrenia, based on transcript levels of Homer1a , an immediate early gene encoding a key molecule of the dendritic spine. Sprague-Dawley rats ( n = 20) were assigned to KET (30 mg/kg) or vehicle (VEH)...
February 22, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36858176/formulation-development-and-molecular-mechanism-characterization-of-long-acting-patches-of-asenapine-for-efficient-delivery-by-combining-api-ils-strategy-and-controlled-release-polymers
#17
JOURNAL ARTICLE
Shoujun Ren, Chao Liu, Yutong Sun, Yang Zhang, Jiuheng Ruan, Liang Fang
The objective of our study, which combined API-ILs strategy and controlled-release polymers, was to prepare a 72 h long-acting drug-in-adhesive patch for optimum delivery of asenapine (ASE). Special attention was paid to the permeation promotion mechanism and the controlled release behavior of ASE-ILs in pressure sensitive adhesives (PSA). Formulation factors were investigated by ex vivo transdermal experiments. The optimized patch was evaluated by pharmacokinetics study and skin irritation test. The obtained formulation was as follows, 15% w/w ASE-MA (about 1136 μg/cm2 ASE, 413 μg/cm2 MA), AACONH2 (Amide adhesive) as the matrix, 80 μm thickness, backing film of CoTran™ 9733...
February 27, 2023: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/36839811/boosting-the-in-vivo-transdermal-bioavailability-of-asenapine-maleate-using-novel-lavender-oil-based-lipid-nanocapsules-for-management-of-schizophrenia
#18
JOURNAL ARTICLE
Fatma Sa'eed El-Tokhy, Mona M A Abdel-Mottaleb, Sherif S Abdel Mageed, Abdulla M A Mahmoud, Elsayed A El-Ghany, Ahmed S Geneidi
Lipid nanocapsules (LNCs) are promising for transdermal drug delivery due to their higher permeability-enhancing effects compared to polymeric nanoparticles. Lavender oil is an essential oil consisting of several terpenes (primarily linalool and linalyl acetate) known for their profound permeation-enhancing action. In the present work, we successfully encapsulated asenapine maleate (a second-generation antipsychotic that is highly metabolized by the liver, reducing its oral bioavailability) into biocompatible LNCs for transdermal application using a novel oily phase, i...
February 1, 2023: Pharmaceutics
https://read.qxmd.com/read/36789916/comparison-of-antipsychotic-dose-equivalents-for-acute-bipolar-mania-and-schizophrenia
#19
JOURNAL ARTICLE
Chia-Ling Yu, Andre F Carvalho, Trevor Thompson, Tzu-Cheng Tsai, Ping-Tao Tseng, Chih-Wei Hsu, Tien-Wei Hsu, Chih-Sung Liang
QUESTION: Are antipsychotic dose equivalents between acute mania and schizophrenia the same? STUDY SELECTION AND ANALYSIS: Six databases were systematically searched (from inception to 17 September 2022) to identify blinded randomised controlled trials (RCTs) that used a flexible-dose oral antipsychotic drug for patients with acute mania. The mean and SD of the effective dose and the pre-post changes in manic symptoms were extracted. A network meta-analysis (NMA) under a frequentist framework was performed to examine the comparative efficacy between the antipsychotics...
February 2023: BMJ Ment Health
https://read.qxmd.com/read/36700326/efficacy-of-asenapine-in-drug-resistant-psychotic-patients-with-dopamine-supersensitivity-psychosis-two-cases
#20
Nobuhisa Kanahara, Hiroshi Kimura, Toshihiko Kinoshita, Masaomi Iyo, Yoshiteru Takekita
Dopamine supersensitivity psychosis (DSP) is an unstable clinical condition observed in individuals with schizophrenia who have been treated with an antipsychotic medication at a high dosage and/or for a long period. An up-regulation of dopamine D2 receptors (DRD2) is thought to be involved in the essential pathology of DSP. An antipsychotic agent with both tight binding to DRD2 and a long half-life is generally effective for treating DSP, but a patient who meets the criteria of treatment-resistant schizophrenia sometimes needs treatment with clozapine...
February 28, 2023: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
keyword
keyword
80739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.